

APR 23 2002

COPY OF PAPERS
ORIGINALLY FILEDattala
paper #9

SHEET 1 OF 1

TECH CENTER 1600/2900

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

FILING DATE: February 9, 2001 GROUP: 1644

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>David</i>	B1	WO 99/43713	9/2/1999	PCT	/	/		No	Yes

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>David</i>	C1	Batova et al., "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ," <u>Clinical Cancer Research</u> , <u>5</u> : 4259-4263 (1999).
<i>David</i>	C2	Gillies et al., "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , <u>59</u> : 2159-2166 (1999).
<i>David</i>	C3	Kendra et al., "Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol Immunother</u> , <u>48</u> : 219-229 (1999).

EXAMINER *David A Saemundson* DATE CONSIDERED *5/28/02*

2302225_1

APR 25 2002

RECEIVED